NEW YORK & SOMERSET, N.J. --(BUSINESS WIRE)--Jun. 17, 2019-- IVERIC bio, Inc. (NASDAQ: ISEE) and Catalent Biologics , today announced that they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC bio’s gene therapy product

- Conference Call and Webcast Today, May 8, 2019 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--May 8, 2019-- IVERIC bio (Nasdaq: ISEE) today announced financial and operating results for the first quarter ended March 31, 2019 and provided a business update.

NEW YORK --(BUSINESS WIRE)--May 1, 2019-- IVERIC bio (Nasdaq:ISEE) today announced that it will report its first quarter 2019 financial and operating results on Wednesday, May 8, 2019 . Following the announcement, IVERIC bio’s management team will host a live conference call and webcast at 8:00